Intent of Surgery for IPMN
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Intraductal Papillary Mucinous Neoplasm. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, China, Germany, Italy, Netherlands
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Optimizing Preoperative Surgical Decision-making for Intraductal Papillary Mucinous Neoplasms: The Role of Intent of Surgery
Overview
This multicenter retrospective observational cohort study seeks to: 1. Classify surgical intent in patients with resected Intraductal Papillary Mucinous Neoplasms (IPMN) and quantify the proportion of IPMN-associated cancers diagnosed as overt pancreatic cancer with incidental IPMN association on pathology. 2. Compare clinicopathologic features and outcomes between surveillance-detected and incidentally detected IPMN-derived pancreatic cancers. 3. Revise and redefine risk features limited to patients undergoing surgery for IPMN-related indications, identifying optimal predictors of malignant IPMN (high-grade dysplasia or invasive cancer).
Primary outcome measures
- Grade of IPMN on Final Pathology [Time frame: Day 0 (Retrospective Analysis)]
Secondary outcome measures (2)
- Recurrence Free Survival [Time frame: Day 0 (Retrospective Analysis)]
- Overall Survival [Time frame: Day 0 (Retrospective Analysis)]
Eligibility criteria
Inclusion criteria
- All patients (18 years old of greater) who underwent surgical resection for IPMN (including low-, high-grade dysplasia, or invasive carcinoma) between July 1, 2015 and July 1, 2025.
Exclusion criteria
- Patients with concomitant pancreatic ductal adenocarcinoma (PDAC)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
United States · 8 centers
- Mayo Clinic — Phoenix
- Johns Hopkins University — Baltimore
- Massachusetts General Hospital — Boston
- Mayo Clinic — Rochester
- NYU Langone Health — New York
- Memorial Sloan Kettering — New York
- Duke University — Durham
- MD Anderson Cancer Center — Houston
Italy · 2 centers
- San Raffaele Hospital — Milan
- Padua University — Padua
Netherlands · 2 centers
- University of Amsterdam — Amsterdam
- University of Utrecht — Utrecht
China · 1 center
- Nanjing University — Nanjing
Germany · 1 center
- Heidelberg University — Heidelberg
Identifiers
NCT: NCT07216521 · 25-00989